[Fine Chemicals] Latest research progress on ergothioneine in 2025-2026: mechanism analysis, green production, and new application breakthroughs
A breakthrough published in Cell Metabolism in 2025 fully clarified, for the first time, the core pathway by which ergothioneine regulates healthy aging in the body. Using C. elegans and aged rats as models, the study confirmed that ergothioneine can bidirectionally regulate metabolism and the aging process through the CSE-H₂S-protein persulfidation signaling axis. The research shows that ergothioneine acts as a specific substrate for cystathionine γ-lyase (CSE), activating the body's hydrogen sulfide production pathway and regulating persulfidation modifications of more than 300 target proteins. Among these, cytosolic glycerol-3-phosphate dehydrogenase (cGPDH) is the core effector target, effectively boosting NAD⁺ levels in the body and improving oxidative stress damage, metabolic disorders, and muscle decline in aged individuals. Gene knockout experiments confirmed that without CSE or cGPDH, ergothioneine's anti-aging effects completely disappear, establishing the uniqueness of this pathway. Animal experiments confirmed that exogenous ergothioneine supplementation extends lifespan in model organisms, improves vascular microcirculation, and lowers aging marker levels, providing a new theoretical basis for aging intervention. The latest 2026 proteomics research further refined its mechanism, finding that the MPST enzyme is the key core protein for ergothioneine's targeted mitochondrial protection. By binding to MPST, ergothioneine repairs damaged mitochondria, boosts energy metabolism efficiency, and clears reactive oxygen species, blocking oxidative aging at the organelle level. Meanwhile, multiple synergistic experiments confirmed that combining ergothioneine with glutathione and ferulic acid forms a potent antioxidant system, providing data support for optimizing functional formulations.
II. Biomanufacturing technology: domestic high-yield systems break through industry bottlenecks. The industrialization of ergothioneine has long been limited by technical shortcomings: traditional fungal extraction methods have low yield, poor purity, and high cost; early microbial fermentation required adding expensive exogenous amino acids, making large-scale production extremely difficult. In October 2025, a team from the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, completed a technological innovation, constructing an ultra-high-yield, low-cost E. coli synthesis system that completely broke foreign technological monopolies. Using E. coli as the chassis cell, the study achieved full biosynthesis of ergothioneine through multi-module reconstruction of metabolic pathways, modification of key rate-limiting enzymes, and redistribution of intracellular metabolic flux, without adding expensive precursor amino acids. The optimized strain's fermentation yield increased substantially, far exceeding existing reported levels at home and abroad, while simplifying purification processes and improving product purity, greatly reducing production costs and solving the industry's core pain points. This green manufacturing technology abandons traditional high-pollution, high-cost processes and is suitable for industrial large-scale production, laying the industrial foundation for widespread application of ergothioneine.
III. New progress in application research: clinical and functional breakthroughs in multiple fields
Comments
0